Pernix Therapeutics Holdings (AMEX: PTX) reported earnings on Nov. 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Pernix Therapeutics Holdings beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share contracted to a loss.
Margins shrank across the board.
Pernix Therapeutics Holdings recorded revenue of $18.1 million. The six analysts polled by S&P Capital IQ expected a top line of $15.5 million on the same basis. GAAP reported sales were 6.3% higher than the prior-year quarter's $17.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.01. The six earnings estimates compiled by S&P Capital IQ averaged $0.03 per share. GAAP EPS were -$0.01 for Q3 against $0.08 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 57.2%, 50 basis points worse than the prior-year quarter. Operating margin was -3.8%, 2,460 basis points worse than the prior-year quarter. Net margin was -1.5%, 1,320 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $28.9 million. On the bottom line, the average EPS estimate is $0.20.
Next year's average estimate for revenue is $69.7 million. The average EPS estimate is $0.24.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is buy, with an average price target of $13.50.